{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:26:16Z","timestamp":1789806376886,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clim.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T04:31:15Z","timestamp":1477629075000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Ebola virus vaccines: Where do we stand?"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-643X","authenticated-orcid":false,"given":"Vincent","family":"Pavot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2016.10.016_bb0005","doi-asserted-by":"crossref","first-page":"g7348","DOI":"10.1136\/bmj.g7348","article-title":"Ebola virus disease","volume":"349","author":"Beeching","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clim.2016.10.016_bb0010","unstructured":"2014 Ebola Outbreak in West Africa - Case Counts|Ebola Hemorrhagic Fever|CDC, (n.d.). http:\/\/www.cdc.gov\/vhf\/ebola\/outbreaks\/2014-west-africa\/case-counts.html (accessed September 20, 2016)."},{"key":"10.1016\/j.clim.2016.10.016_bb0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.clim.2016.10.016_bb0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014e\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clim.2016.10.016_bb0035","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet. Lond. Engl."},{"key":"10.1016\/j.clim.2016.10.016_bb0040","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.clim.2016.10.016_bb0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine \u2014 preliminary Report","author":"Regules","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0050","first-page":"776","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","volume":"373","author":"Ledgerwood","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0055","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.clim.2016.10.016_bb0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fvl.09.56","article-title":"Ebolavirus glycoprotein structure and mechanism of entry","volume":"4","author":"Lee","year":"2009","journal-title":"Futur. Virol."},{"key":"10.1016\/j.clim.2016.10.016_bb0070","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.10.016_bb0075","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2016.10.016_bb0080","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2016.10.016_bb0085","doi-asserted-by":"crossref","first-page":"i386","DOI":"10.1136\/bmj.i386","article-title":"Ebola vaccine will be made available for emergency use","volume":"532","author":"Gulland","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clim.2016.10.016_bb0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2016.10.016_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2016.10.016_bb0100","unstructured":"Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production|Johnson & Johnson, (n.d.). http:\/\/www.jnj.com\/news\/all\/Johnson-Johnson-Announces-Major-Commitment-to-Speed-Ebola-Vaccine-Development-and-Significantly-Expand-Production (accessed September 20, 2016)."},{"key":"10.1016\/j.clim.2016.10.016_bb0105","unstructured":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02509494 (accessed September 20, 2016)."},{"key":"10.1016\/j.clim.2016.10.016_bb0110","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.93.8.3602","article-title":"The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing","volume":"93","author":"Sanchez","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2016.10.016_bb0115","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1086\/514282","article-title":"Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates","volume":"179","author":"Sanchez","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2016.10.016_bb0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616305368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616305368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T23:50:00Z","timestamp":1568505000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616305368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":24,"alternative-id":["S1521661616305368"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2016.10.016","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ebola virus vaccines: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}